CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer

Xiaofei Zhang, Hideki Shimodaira, Hiroshi Soeda, Keigo Komine, Hidekazu Takahashi, Kota Ouchi, Masahiro Inoue, Masanobu Takahashi, Shin Takahashi, Chikashi Ishioka

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: The CpG island methylator phenotype (CIMP) with multiple promoter methylated loci has been observed in a subset of human colorectal cancer (CRC) cases. CIMP status, which is closely associated with specific clinicopathological and molecular characteristics, is considered a potential predictive biomarker for efficacy of cancer treatment. However, the relationship between the effect of standard chemotherapy, including cytotoxic drugs and anti-epidermal growth factor receptor (EGFR) antibodies, and CIMP status has not been elucidated. Methods: In 125 metastatic colorectal cancer (mCRC) patients, we investigated how clinical outcome of chemotherapy was related to CIMP status as detected by methylation-specific PCR (MSP) and to genetic status in five EGFR-related genes (KRAS, BRAF, PIK3CA, NRAS, and AKT1) as detected by direct sequencing. Results: CIMP-positive status was significantly associated with proximal tumor location and peritoneum metastasis (all P values <0.05). The progression-free survival of patients with CIMP-positive tumors receiving sequential therapy with FOLFOX as the first-line treatment followed by irinotecan-based therapy as the second-line treatment (median = 6.6 months) was inferior to that of such patients receiving the reverse sequence (median = 15.2 months; P = 0.043). Furthermore, CIMP-positive tumors showed higher mutation frequencies for the five EGFR-related genes (74.1 %) than the CIMP-negative tumors did (50.0 %). Among the KRAS wild-type tumors, CIMP-positive tumors were associated with a worse clinical outcome than CIMP-negative tumors following anti-EGFR antibody therapy. Conclusion: Sequential FOLFOX followed by an irinotecan-based regimen is unfavorable in patients with CIMP-positive tumors. High frequencies of mutation in EGFR-related genes in CIMP-positive tumors may cause the lower response to anti-EGFR antibody therapy seen in patients with wild-type KRAS and CIMP-positive tumors.

Original languageEnglish
Pages (from-to)1091-1101
Number of pages11
JournalInternational Journal of Clinical Oncology
Volume21
Issue number6
DOIs
Publication statusPublished - 2016 Dec 1

Keywords

  • Anti-EGFR antibody
  • BRAF
  • CpG island methylator phenotype
  • Irinotecan- and oxaliplatin-based chemotherapy
  • Metastatic colorectal cancer
  • RAS

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer'. Together they form a unique fingerprint.

  • Cite this